Perceptive Life Sciences, a fund that has outperformed the market, sold all of its 1 million shares of Novavax in the first few months of 2021 and bought millions more shares of three biopharma/biotech stocks in the same period.
After trailing the broader market for the past few months, biotech has gotten some love in recent days – from the FDA in the form of its approval of Biogen’s controversial Alzheimer’s drug, and also from the Reddit crowd.
As PDUFA dates can serve as catalysts for stocks, biotech investors can be well served by paying attention to them.
What do these impending decisions mean for healthcare and biotech stocks?
A year or so ago, the gene therapy trend was hot – until it quickly cooled down. But now may be the time to get back in on this trend, especially with one particular biotech stock.
The biotech featured in today’s article “selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a significant benefit over existing products.”
Companies involved in biopharmaceuticals, life sciences, stem cell therapies, COVID test kits and traumatic brain injury treatment using psychedelic and naturally-sourced therapies are among the slew of new biotech stocks to watch.
“When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.”
The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from current levels.
After a massive rally last year, biotech stocks have underperformed since February of this year. The author of today’s article, however, believes that the selloff… Read More »Why These 2 Biotech Stocks Could Be Must-Owns This May